Disruptive Pharma (DPHA) Q3 2024 earnings summary

Executive summary

• First patient dosed in phase 2b POINTER study for RMC-035 in open heart surgery; study also initiated in Europe.

• Results from phase 2a AKITA study published in eClinical Medicine, confirming clinical relevance of RMC-035.

• No revenue generated; focus remains on R&D and clinical advancement.

Financial highlights

• Net sales for Q3 and Jan–Sep 2024: 0 KSEK (0 KSEK year-over-year).

• Net loss Q3: -31,727 KSEK (vs. -23,342 KSEK); Jan–Sep: -70,108 KSEK (vs. -96,227 KSEK).

• EPS Q3: -2.65 SEK (vs. -2.32 SEK); Jan–Sep: -6.51 SEK (vs. -9.56 SEK).

• Cash and equivalents at Sep 30: 66,775 KSEK (vs. 103,195 KSEK).

• Equity at Sep 30: 63,287 KSEK (vs. 83,132 KSEK).

Outlook and guidance

• Patient recruitment for POINTER expected to last about one year; topline results anticipated six months after completion.

• First interim safety analysis from POINTER expected in Q1 2025.

• Continued focus on executing POINTER study and expanding clinical sites.